Hello Sharon, This is an awesome initiative. I can appreciate how valuable this project for the people that suffer from Asthma. Growing up, it was hard to see my Dad quickly drift in emergency especially overnight time and again. I am glad you and your team are going after a p...

Dear Prakash, Thank you for your kind words, for sharing your story about your Dad, and for your investment! I understand completely - my attacks always seemed to be worse at night, and at Christmas time, and it made for some scary experiences. I can't agree with you more about Wefunder and this ONE great community. Also, not for nothing, I'm a great fan of a well-placed ellipsis like yours ... I appreciate your interest in a call as well. I sent you an email with some times for us to connect...

As a respiratory therapist and a physician assistant, I'm always looking to seek out and support devices/companies that make a big impact on the patients I care for. This seems like a really innovative product. How does what the device hears/senses, does that correlate with me...

Dear Adam, First, I just have to say it - did you know our device was first called ADAM when it was conceived in the mind of a brilliant researcher at the University of Rochester? We added an extra M, so now it's called ADAMM, but I just had to point that out. As you can see from our model, we value Respiratory Therapists significantly - so thank you for the work you do both as an RT and a PA. We are thrilled to lead a company where Respiratory Therapists can fulfil their calling around self-...

If I invest now do I get the Early Bird Bonus? I see EARLY BIRD TERMS: $130,045 LEFT

Hello Grigore! Yes, absolutely, if you invest now you still get the early bird terms.

Hello Sharon, Really appreciate the direction you're taking with ADAMM. Could you provide more detail on how the AI is utilized within the platform? Specifically, does the AI learn from individual patient data—or even across all patients—to continually improve the guidance and...

Great question Maxime! And thank you for your kind words. For clarity going forward, we use the word members interchangeably with patients. We use AI in a couple ways and are going to expand our uses with this fund raise. As long as our members consent, we use the data to continually improve what we call our actionable insights. This could be data from one member used in their own feedback loop, or data across members to train recognition of various sounds. We utilize multiple sensors in the ...

Hi Sharon, I’m Zac with D3VC. We specialize in investment crowdfunding and are intrigued by your offering, especially given your team's expertise. I’d love to learn more about your experience with AI—how do you plan to incorporate it into your product development? Specifically...

Zac, thanks for the insightful questions, and have to say I appreciate D3VC's data-driven approach to identifying who to diligence for investment. It's very akin to our approach - eliminating bias that tends to be inherent in so many of the standard measures that are used in respiratory testing and diagnosis today. We like to say that the sound of our deep organs doesn't depend on race, ethnicity or zip code, and therefore we have unparalleled, non-invasive objective insights to inform mass p...

Health Care Originals Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

7.5x revenue growth since September 2025; on track for $1M MRR and cash-flow positivity in 2027

$129M ARR pipeline for Respiratory Care; 36 insurers in 11 states cover Neuro Care

$12M raised from venture funds including Safar Partners, Chloe Capital, Kingscrowd Capital, D3VC.ai

67% of users report zero asthma or COPD attacks within 6 months

26 patents issued & pending, including 2 AI patents

2 AI agents deployed to predict crises from patient data & scale patient outreach

Featured in Forbes, USA Today, Masters of Scale, AAFA, & Kingscrowd; PurposeBuilt100 honoree

Unlocking a $900B+ opportunity across chronic health conditions by preventing emergency care

Health Care Originals

Quick facts

Investor memo sources

Team profiles

Featured investor profiles

Updates